CTOs on the Move


 
ZAGENO is on a mission to accelerate scientific innovation by streamlining biotech purchasing processes with its award-winning, first-of-its-kind e-commerce platform. With over 25 million product SKUs available from more than 5,000 unique product brands, ZAGENO makes online shopping for any research material convenient, efficient and reliable. The ZAGENO experience includes its Scientific Score, a best-in-class product rating system that offers unbiased, peer-reviewed ratings to support accurate purchasing decisions. Available on desktop, tablet, and mobile devices, ZAGENO makes biotech purchases easier than ever and is an ideal sales channel for suppliers and partners. Founded in 2015, the company is headquartered in ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.zageno.com
  • 625 Massachusetts Avenue
    Cambridge, MA USA 02139
  • Phone: 617.855.5944

Executives

Name Title Contact Details
Sandeep Aji
Chief Technology Officer Profile

Funding

Zageno raised $20M on 04/23/2019

Similar Companies

Garuda Therapeutics

Garuda Therapeutics seeks to create a world which eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 70 diseases.

Gotham Therapeutics

Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins.

Gliknik

Gliknik Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders.

Vaxin

Vaxin is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Vaxin is able to rationally design and rapidly develop immunotherapeutic products tailored to address the a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer with fundamental advantages over competing products. Our mission at Vaxin is to protect and preserve public health by providing effective and safe vaccines that prevent disease outbreak.